Other commonly mutated genes among the analyzed AML samples were TP53 (19%), TET2 (19%), NPM1 (17%), IDH1/2 (14%), SRSF2 (14%), RUNX1 (14%), SF3B1 (9%), CEBPA (8%) and KIT (3%). This evidence concerns the gene TP53 and acute myeloid leukemia.